Local tetrahydrobiopterin administration augments cutaneous vasoconstriction in aged humans.
Reflex vasoconstriction (VC) is attenuated in aged skin resulting in greater skin blood flow and heat loss during cold exposure. We hypothesized that adrenergic function is compromised due to depletion of tetrahydrobiopterin (BH(4)), an essential cofactor required for catecholamine synthesis, and therefore local BH(4) supplementation would functionally augment reflex and pharmacologically induced VC elicited by gradual whole-body cooling (skin temperature (T(sk)) = 30.5 degrees C) and tyramine infusion, respectively. Four microdialysis (MD) fibres were placed in the forearm skin of 11 young (Y) and 11 older (O) human subjects for infusion of (1) Ringer solution (control), (2) 5 mM BH(4), (3) 5 mM BH(4) + 10 mM ascorbate, and (4) 5 mM BH(4) + adrenoreceptor blockade (5 mM yohimbine + 1 mM propranolol). Laser Doppler flux (LDF) was measured over each MD site and cutaneous vascular conductance was calculated as CVC = LDF/MAP and expressed as per cent change from baseline (% DeltaCVC(base)). The VC response was lower at the control site in O during cooling (Y: -34 +/- 2% DeltaCVC(base), O: -17 +/- 2% DeltaCVC(base); P < 0.001) and tyramine infusion (Y: - 33 +/- 4% DeltaCVC(base), O: -15 +/- 3% DeltaCVC(base); P < 0.001). BH(4) infusion normalized O to Y values during both cooling (Y: -34 +/- 4% DeltaCVC(base), O: -34 +/- 2% DeltaCVC(base); P < 0.001) and tyramine (Y: -38 +/- 4% DeltaCVC(base), O: -35 +/- 3% DeltaCVC(base); P < 0.001), however, adding adrenoreceptor blockade abolished VC in aged skin indicating that BH(4) acts through adrenergic, not cotransmitter, mechanisms. Local BH(4) supplementation augments reflex and tyramine-induced VC in aged skin, suggesting that reduced BH(4) bioavailability may contribute to attenuated VC during whole-body cooling.
Lang
James A
JA
Department of Kinesiology, The Pennsylvania State University, 229 Noll Lab, University Park, PA 16802, USA. jal493@psu.edu
Holowatz
Lacy A
LA
Kenney
W Larry
WL
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000328:Adult; D000368:Aged; D000375:Aging / Q000502:physiology*; D001708:Biopterins / Q000031:analogs & derivatives* / Q000494:pharmacology; D001831:Body Temperature / Q000502:physiology*; D003080:Cold Temperature; D005260:Female; D006801:Humans; D008297:Male; D019001:Nitric Oxide Synthase / Q000378:metabolism; D011433:Propranolol / Q000494:pharmacology; D012039:Regional Blood Flow / Q000187:drug effects* / Q000502:physiology; D012867:Skin / Q000098:blood supply*; D013566:Sympathomimetics / Q000494:pharmacology; D014439:Tyramine / Q000494:pharmacology; D014661:Vasoconstriction / Q000187:drug effects* / Q000502:physiology; D015016:Yohimbine / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D013566:Sympathomimetics; D001708:Biopterins; D015016:Yohimbine; D011433:Propranolol; D019001:Nitric Oxide Synthase; C003402:sapropterin; D014439:Tyramine